HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo

• Hongbiao Huang ,

  Contributed equally to this work with: Hongbiao Huang, Ningning Liu, Changshan Yang

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Ningning Liu ,

  Contributed equally to this work with: Hongbiao Huang, Ningning Liu, Changshan Yang

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Changshan Yang ,

  Contributed equally to this work with: Hongbiao Huang, Ningning Liu, Changshan Yang

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Siyan Liao,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Haiping Guo,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Kai Zhao,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Xiaofen Li,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Shouting Liu,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Lixia Guan,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Chunjiao Liu,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Li Xu,

  Affiliations Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China, Department of Hematology, The People’s Hospital of Guangxi Autonomous Region, Nanning, Guangxi, People’s Republic of China

  ⨯
• Change Zhang,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Wenbin Song,

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• Bing Li,

  Affiliation Experimental Medical Research Center, Guangzhou Medical College, Guangzhou, Guangdong, People’s Republic of China

  ⨯
• Ping Tang,

  Affiliations Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China, Department of Hematology, The Affiliated Guangzhou first Municipal People’s Hospital of Guangzhou Medical College, Guangzhou, Guangdong, People’s Republic of China

  ⨯
• Q. Ping Dou ,

  * E-mail: Liujinbao1@yahoo.com.cn (JL); doup@karmanos.org (QD)

  Affiliations Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China, The Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America

  ⨯
•  [ ... ],
• Jinbao Liu

  * E-mail: Liujinbao1@yahoo.com.cn (JL); doup@karmanos.org (QD)

  Affiliation Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical College, Guangdong, People’s Republic of China

  ⨯
• [ view all ]
• [ view less ]